Download - Drug Development
![Page 1: Drug Development](https://reader030.vdocuments.us/reader030/viewer/2022020101/54701fc4b4af9f91628b45f1/html5/thumbnails/1.jpg)
DRUG DEVELOPMENT
A view on the process from the idea to the registered pharmaceutical
Dr. Matthias Kreuter
Head of Alpinia Laudanum Institute of Phytopharmaceutical Sciences AG Walenstadt, Switzerland
![Page 2: Drug Development](https://reader030.vdocuments.us/reader030/viewer/2022020101/54701fc4b4af9f91628b45f1/html5/thumbnails/2.jpg)
Organisation of the presentation
I. DISCOVERY
Identification of target and resource
![Page 3: Drug Development](https://reader030.vdocuments.us/reader030/viewer/2022020101/54701fc4b4af9f91628b45f1/html5/thumbnails/3.jpg)
Organisation of the presentation
II. HIT GENERATION
Perspectives: A) Research and DevelopmentB) Quality Control and ProductionC) Marketing Authorisation
![Page 4: Drug Development](https://reader030.vdocuments.us/reader030/viewer/2022020101/54701fc4b4af9f91628b45f1/html5/thumbnails/4.jpg)
Organisation of the presentation
III. LEAD GENERATION
Perspectives: A) Research and DevelopmentB) Quality Control and ProductionC) Marketing Authorisation
![Page 5: Drug Development](https://reader030.vdocuments.us/reader030/viewer/2022020101/54701fc4b4af9f91628b45f1/html5/thumbnails/5.jpg)
Organisation of the presentation
IV. CLINICAL DEVELOPMENT
Perspectives: A) Research and DevelopmentB) Quality Control and ProductionC) Marketing Authorisation
![Page 6: Drug Development](https://reader030.vdocuments.us/reader030/viewer/2022020101/54701fc4b4af9f91628b45f1/html5/thumbnails/6.jpg)
Organisation of the presentation
V. POST REGISTRATION
Perspectives: A) Research and DevelopmentB) Quality Control and ProductionC) Marketing Authorisation
![Page 7: Drug Development](https://reader030.vdocuments.us/reader030/viewer/2022020101/54701fc4b4af9f91628b45f1/html5/thumbnails/7.jpg)
I. DISCOVERY
Identification of target and resource
![Page 8: Drug Development](https://reader030.vdocuments.us/reader030/viewer/2022020101/54701fc4b4af9f91628b45f1/html5/thumbnails/8.jpg)
Target identification
- Area of interest in terms of drug indication ?
- Relevant cellular or molecular targets ?
- Appropriate assays – established or to be developed ?
- Available relevant literature ?
- Patent situation in the target area ?
I. DISCOVERY
![Page 9: Drug Development](https://reader030.vdocuments.us/reader030/viewer/2022020101/54701fc4b4af9f91628b45f1/html5/thumbnails/9.jpg)
Resource identification
Potential resources for novel drugs:
- Natural organisms (plants, fungi, bacteria, animals)
- Combinatorial chemistry
- Structure-based drug design
Methods for drug discovery:
- High throughput screening of random samples (HTS):Including screen development, primary and secondary
screening
- Ethnobiological approach:Traditional use of natural organisms for medicines
I. DISCOVERY
![Page 10: Drug Development](https://reader030.vdocuments.us/reader030/viewer/2022020101/54701fc4b4af9f91628b45f1/html5/thumbnails/10.jpg)
Resource identification - Alpinia Institute
Natural organisms , in particular plants
I. DISCOVERY
Medicinal plants continue to play a significant role as a resource for the discovery of novel drugs (1)
1) Balunas and Koinghorn, Life Sci 2005.
![Page 11: Drug Development](https://reader030.vdocuments.us/reader030/viewer/2022020101/54701fc4b4af9f91628b45f1/html5/thumbnails/11.jpg)
Resource identification - Alpinia Institute
Natural organisms , in particular plants
- 52% of the drugs approved in the U.S. from 1981-2002 were natural products or derived from them (2).
- 26 plant based drugs were approved during 2000-2006,including novel-molecular based drugs (3).
- In the future multicomponent botanical therapeutics will experience an increasing interest in biomedicine (4).
I. DISCOVERY
Medicinal plants continue to play a significant role as a resource for the discovery of novel drugs (1)
2) Newman, J Nat Pr 2002. 3) Saklani & Kutty, Drug Disc Today 2008. 4) Schmidt et al., Nature Chem Biol 2007.
![Page 12: Drug Development](https://reader030.vdocuments.us/reader030/viewer/2022020101/54701fc4b4af9f91628b45f1/html5/thumbnails/12.jpg)
Method of drug discovery - Alpinia Institute
Ethnobotanical approach
Systematic screening of:
- Published literature on traditional medicinal plant use (e.g. documented traditional healers‘ experience)
- Historical texts(e.g. ancient botanico-medicinal manuscripts)
Advantages: - Preselection of potentially active resources- Promising safety profile (age-long
experience)- Cost-efficient and comparatively fast
I. DISCOVERY
![Page 13: Drug Development](https://reader030.vdocuments.us/reader030/viewer/2022020101/54701fc4b4af9f91628b45f1/html5/thumbnails/13.jpg)
II. HIT GENERATION
Perspectives: A) Research and DevelopmentB) Quality Control and ProductionC) Marketing Authorisation
![Page 14: Drug Development](https://reader030.vdocuments.us/reader030/viewer/2022020101/54701fc4b4af9f91628b45f1/html5/thumbnails/14.jpg)
Process development – in phytopharmacy
Herbal raw material
Extraction solvent
Extraction
Miscella (Liquid raw extract)
Encapsulatable mass
Dry extract Liquid extract, tincture
Soft capsulesLiquids, drops, ointments
Tablets, hard capsules
II. HIT GENERATIONA) RESEARCH AND DEVELOPMENT
![Page 15: Drug Development](https://reader030.vdocuments.us/reader030/viewer/2022020101/54701fc4b4af9f91628b45f1/html5/thumbnails/15.jpg)
Development of the test substance
Define: - Active substance (in phytopharmacy: native extract )- Dosage form
Establish: - Physico-chemical profile (active compounds, marker)
Investigate: - Pharmacology- Mode of action
Prepare: - Patent draft
II. HIT GENERATIONA) RESEARCH AND DEVELOPMENT
![Page 16: Drug Development](https://reader030.vdocuments.us/reader030/viewer/2022020101/54701fc4b4af9f91628b45f1/html5/thumbnails/16.jpg)
Raw material supply
Availability of raw materials, excipients, consumables
Herbal raw material
- Established market product ?
- Contract cultivation ?
- Wild harvesting ?
Pay attention to: - Continuous availability
- Quality variations
- Sustainable cultivation / harvesting
- Biodiversity regulations
- Existing patent and intellectual property rights
II. HIT GENERATIONB) QUALITY CONTROL AND PRODUCTION
![Page 17: Drug Development](https://reader030.vdocuments.us/reader030/viewer/2022020101/54701fc4b4af9f91628b45f1/html5/thumbnails/17.jpg)
Identity test, controls
Monographs in pharmacopoeias for:
- Chemical substances
- Herbal raw materials
Organisation of a monograph
Definition: chemical characterisation
Characters: appearance, solubility
Identification: microscopy, physico-chemical tests
Tests: qualitative analysis
Assay: quantitative analysis
Impurities: chemical or microbiological impurities
II. HIT GENERATIONB) QUALITY CONTROL AND PRODUCTION
![Page 18: Drug Development](https://reader030.vdocuments.us/reader030/viewer/2022020101/54701fc4b4af9f91628b45f1/html5/thumbnails/18.jpg)
In house controls
Two standard analytical methods in phytopharmacy:
- TLC = Thin layer chromatography
- HPLC = High performance liquid chromatography
II. HIT GENERATIONB) QUALITY CONTROL AND PRODUCTION
Minutes
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28
mAU
0
50
100
150
200
250
300
mAU
0
50
100
150
200
250
300
14.800 3943972
DAD-CH1 218 nmCN002.E12.C01 control
Retention TimeArea
![Page 19: Drug Development](https://reader030.vdocuments.us/reader030/viewer/2022020101/54701fc4b4af9f91628b45f1/html5/thumbnails/19.jpg)
CTD documentation
II. HIT GENERATIONC) MARKETING AUTHORISATION PROCESS
Common Technical Document:
Harmonised format for applications
for preparing marketing authorisation
in the three ICH* regions (Europe,
Japan, USA)
Module 1:Information
Module 2:Summaries
Module 3:Quality
Module 4:Non clinical study reports
Module 5:Clinical study reports
Structure of the CTD
*ICH: International conference for harmonisation of technical requirements for registration of pharmaceuticals for human use.
![Page 20: Drug Development](https://reader030.vdocuments.us/reader030/viewer/2022020101/54701fc4b4af9f91628b45f1/html5/thumbnails/20.jpg)
CTD documentation
Prepare Module 3 : Quality
- Monograph
- Specification
- Development report (on going)
II. HIT GENERATIONC) MARKETING AUTHORISATION PROCESS
Module 1:Information
Module 2:Summaries
Module 3 :Quality
Module 4:Non clinical study reports
Module 5:Clinical study reports
![Page 21: Drug Development](https://reader030.vdocuments.us/reader030/viewer/2022020101/54701fc4b4af9f91628b45f1/html5/thumbnails/21.jpg)
II. HIT GENERATIONA) RESEARCH AND DEVELOPMENT
Preclinical development
In vitro profiling:
- Biochemical assays (e.g. enzyme activity assays)
- Cell culture assays (e.g. cancer cell lines)
- Isolated tissue assays (e.g. mucosa model)
In vitro toxicology:
Investigate potential toxic effects
in bacteria- or cell cultures
![Page 22: Drug Development](https://reader030.vdocuments.us/reader030/viewer/2022020101/54701fc4b4af9f91628b45f1/html5/thumbnails/22.jpg)
II. HIT GENERATIONA) RESEARCH AND DEVELOPMENT
Working with cell cultures
Cells are kept in liquid nitrogen.
Medium and culture flasks for cell cultures.
Medium for cell cultures is pipetted into a culture flask.
Cultivation of cell cultures in petri-dishes or cell plates
with the addition of test substances.
Changes of the cultivated cells are evaluated under the micro-scope after the addition of a test substance.
![Page 23: Drug Development](https://reader030.vdocuments.us/reader030/viewer/2022020101/54701fc4b4af9f91628b45f1/html5/thumbnails/23.jpg)
III. LEAD GENERATION
Perspectives: A) Research and DevelopmentB) Quality Control and ProductionC) Marketing Authorisation
![Page 24: Drug Development](https://reader030.vdocuments.us/reader030/viewer/2022020101/54701fc4b4af9f91628b45f1/html5/thumbnails/24.jpg)
III. LEAD GENERATIONA) RESEARCH AND DEVELOPMENT
Preclinical development
In vivo testing Animal model (mouse or rat)
Drug action: - Behaviour and reaction
- Physiology
- Histopathology
Toxicology: - Acute toxicity
- Subchronic toxicity
- Tissue specific toxicity
- Tolerability
Consider ethical aspects (e.g. number and kind of animals
used)
![Page 25: Drug Development](https://reader030.vdocuments.us/reader030/viewer/2022020101/54701fc4b4af9f91628b45f1/html5/thumbnails/25.jpg)
III. LEAD GENERATIONA) RESEARCH AND DEVELOPMENT
Preclinical development (continued)
Pharmacokinetic studies What does the body to the
drug ?
Investigate: - Liberation
- Absorption
- Distribution
- Metabolism
- Excretion
Pharmacodynamic studies What does the drug to the body ?
Investigate: - Physiological effects
- Drug action
- Relationship between drug concentration and effect
![Page 26: Drug Development](https://reader030.vdocuments.us/reader030/viewer/2022020101/54701fc4b4af9f91628b45f1/html5/thumbnails/26.jpg)
III. LEAD GENERATIONA) RESEARCH AND DEVELOPMENT
Preclinical development (continued)
Patent policy
Explore the related patent environment:
Develop a patent strategy:
Database of the European Patent Office (espacencet)
- Rationale- Possibilities- Desired strength- Costs
![Page 27: Drug Development](https://reader030.vdocuments.us/reader030/viewer/2022020101/54701fc4b4af9f91628b45f1/html5/thumbnails/27.jpg)
III. LEAD GENERATIONB) QUALITY CONTROL AND PRODUCTION
Scaling up
Scaling up from laboratory to production sizeGMP and GLP environments
Validation
Conduct a process validation including various batch sizes
Stability testing
Conduct a stability test under different conditions of temperature, humidity and exposure time
![Page 28: Drug Development](https://reader030.vdocuments.us/reader030/viewer/2022020101/54701fc4b4af9f91628b45f1/html5/thumbnails/28.jpg)
III. LEAD GENERATIONC) MARKETING AUTHORISATION PROCESS
CTD documentation
Continue Module 3 : Quality
Prepare Module 4 : Non clinical study reports
- Validation report
- Stability report
- Manufacturing protocol
- Development report (on going)
Module 1:Information
Module 2:Summaries
Module 3 :Quality
Module 4 :Non clinical study reports
Module 5:Clinical study reports
![Page 29: Drug Development](https://reader030.vdocuments.us/reader030/viewer/2022020101/54701fc4b4af9f91628b45f1/html5/thumbnails/29.jpg)
IV. CLINICAL DEVELOPMENT
Perspectives: A) Research and DevelopmentB) Quality Control and ProductionC) Marketing Authorisation
![Page 30: Drug Development](https://reader030.vdocuments.us/reader030/viewer/2022020101/54701fc4b4af9f91628b45f1/html5/thumbnails/30.jpg)
IV. CLINICAL DEVELOPMENTA) RESEARCH AND DEVELOPMENT
Clinical development – “ Linking bench to bedside”
Clinical drug studies – Research in humans
Subject to ethical concern:
- Qualify to increase existing knowledge
- Respect freedom of decision of volunteers
- Involve a substantiated risk-benefit assessment
The realisation of a clinical drug study has to be approved by an
Independent Ethics Commitee (IEC).
![Page 31: Drug Development](https://reader030.vdocuments.us/reader030/viewer/2022020101/54701fc4b4af9f91628b45f1/html5/thumbnails/31.jpg)
IV. CLINICAL DEVELOPMENTA) RESEARCH AND DEVELOPMENT
Clinical development – “ Linking bench to bedside”
Phase I studies 20 to 30 healthy volunteers
Investigate: - Safety and tolerability
- Pharmacokinetics
- Pharmacodynamics
Treatment groups
toxic
therapeutic
subtherapeutic
Dos
age
(mg)
Example: Dose titration - first application in humans
![Page 32: Drug Development](https://reader030.vdocuments.us/reader030/viewer/2022020101/54701fc4b4af9f91628b45f1/html5/thumbnails/32.jpg)
IV. CLINICAL DEVELOPMENTA) RESEARCH AND DEVELOPMENT
Clinical development – “ Linking bench to bedside” (continued)
Phase II studies 100 to 500 patient volunteers
Investigate: - Safety and tolerability
- Pharmacokinetics
- Pharmacodynamics
- Efficiency
- Dosage to effect relationship
Study design: - Dosage comparison
Antitumor drugs: Combination of Phase I and II at an early stage of
drug development is possible.
![Page 33: Drug Development](https://reader030.vdocuments.us/reader030/viewer/2022020101/54701fc4b4af9f91628b45f1/html5/thumbnails/33.jpg)
IV. CLINICAL DEVELOPMENTA) RESEARCH AND DEVELOPMENT
Overall aim of Phase III: Risk-benefit evaluation
Phase III studies are “pivotal studies” = outcome is crucial for the decision taking of the regulatory authorities.
![Page 34: Drug Development](https://reader030.vdocuments.us/reader030/viewer/2022020101/54701fc4b4af9f91628b45f1/html5/thumbnails/34.jpg)
IV. CLINICAL DEVELOPMENTB) QUALITY CONTROL AND PRODUCTION
Clinical samples
Production - Provide appropriate sample quantities (Phase I, II,
III)
- Define sample shipment logistics
Quality control - Prepare complete batch release documentation
- Define short and long term storage of samples
GMP and GLP environments
![Page 35: Drug Development](https://reader030.vdocuments.us/reader030/viewer/2022020101/54701fc4b4af9f91628b45f1/html5/thumbnails/35.jpg)
IV. CLINICAL DEVELOPMENTC) MARKETING AUTHORISATION PROCESS
CTD documentation
- Prepare Modules :
1: Administrative information
2: CTD summaries
5: Clinical study reports
- Compile the whole CTD
Regulatory Authorities
- Submit the completed CTD
- File a New Drug Application with EMEA (Europe) or FDA (USA)
Module 1 :Information
Module 2 :Summaries
Module 3:Quality
Module 4:Non clinical study reports
Module 5 :Clinical study reports
![Page 36: Drug Development](https://reader030.vdocuments.us/reader030/viewer/2022020101/54701fc4b4af9f91628b45f1/html5/thumbnails/36.jpg)
V. POST REGISTRATION
Perspectives: A) Research and DevelopmentB) Quality Control and ProductionC) Marketing Authorisation
![Page 37: Drug Development](https://reader030.vdocuments.us/reader030/viewer/2022020101/54701fc4b4af9f91628b45f1/html5/thumbnails/37.jpg)
V. POST REGISTRATIONA) RESEARCH AND DEVELOPMENT
Clinical development after marketing
Phase IV studies Post marketing testing
Investigate specific questions within the frame of the approved
indication:
- Expanded benefit-risk-profile
- Combination with other drugs
- Optimization (e.g. dosage, application)
E.g.: The worldwide use of the approved drug might lead to the
occurrence of very rare side effects.
Reason for expanded epidemiologic studies
![Page 38: Drug Development](https://reader030.vdocuments.us/reader030/viewer/2022020101/54701fc4b4af9f91628b45f1/html5/thumbnails/38.jpg)
V. POST REGISTRATIONB) PRODUCTION & QC / C) MARKETING AUTHORISATION
Production and quality control
Manufacture - Manufacturing of the product
- Controls acc. to the established batch release
process
GMP and GLP environments
Marketing authorisation process
Approval - Drug is approved for marketing by the Authorities
![Page 39: Drug Development](https://reader030.vdocuments.us/reader030/viewer/2022020101/54701fc4b4af9f91628b45f1/html5/thumbnails/39.jpg)
Summary
I. DISCOVERYIdentify target and resource
II. HIT GENERATIONDevelop process and test substance Conduct in vitro testing
III. LEAD GENERATIONConduct in vivo testingPharmacokinetic and pharmacodynamic studies
IV. CLINICAL DEVELOPMENTHuman trials – Phase I, II, III
V. POST REGISTRATIONHuman trials – Phase IV
![Page 40: Drug Development](https://reader030.vdocuments.us/reader030/viewer/2022020101/54701fc4b4af9f91628b45f1/html5/thumbnails/40.jpg)
Thank you for your attention !